Fully recruited clinical trial in LADA with Diamyd®

The clinical Phase II trial GADinLADA, where the diabetes vaccine Diamyd[®] is administered directly into the lymph node in patients with the autoimmune form of diabetes LADA (Latent Autoimmune Diabetes in Adults), is fully recruited, and the first results from the trial are planned to be announced in early 2022.The first analysis of clinical and immunological parameters will be performed when all patients have been followed for 5 months after their first injection, which means that the results are expected to be presented at the beginning of next year. The patients will be followed for a